News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
494,233 Results
Type
Article (24622)
Company Profile (159)
Press Release (469440)
Multimedia
Podcasts (104)
Webinars (20)
Section
Business (147498)
Career Advice (1540)
Deals (27393)
Drug Delivery (101)
Drug Development (59083)
Employer Resources (149)
FDA (11135)
Job Trends (11208)
News (250771)
Policy (23114)
Tag
Academia (1340)
Accelerated approval (12)
Adcomms (14)
Allergies (82)
Alliances (37539)
ALS (101)
Alzheimer's disease (1047)
Antibody-drug conjugate (ADC) (161)
Approvals (11254)
Artificial intelligence (352)
Autoimmune disease (58)
Automation (22)
Bankruptcy (248)
Best Places to Work (8543)
BIOSECURE Act (19)
Biosimilars (116)
Biotechnology (80)
Bladder cancer (101)
Brain cancer (36)
Breast cancer (310)
Cancer (2765)
Cardiovascular disease (222)
Career advice (1313)
Career pathing (29)
CAR-T (175)
CDC (28)
Cell therapy (471)
Cervical cancer (26)
Clinical research (50841)
Collaboration (1025)
Company closure (1)
Compensation (459)
Complete response letters (40)
COVID-19 (1505)
CRISPR (59)
C-suite (492)
Cystic fibrosis (97)
Data (3506)
Decentralized trials (1)
Denatured (40)
Depression (69)
Diabetes (267)
Diagnostics (4395)
Digital health (25)
Diversity (9)
Diversity, equity & inclusion (34)
Drug discovery (161)
Drug pricing (158)
Drug shortages (28)
Duchenne muscular dystrophy (141)
Earnings (58234)
Editorial (41)
Employer branding (17)
Employer resources (125)
Events (73399)
Executive appointments (825)
FDA (13062)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (3)
Frontotemporal dementia (11)
Funding (856)
Gene editing (120)
Generative AI (32)
Gene therapy (361)
GLP-1 (630)
Government (2928)
Grass and pollen (5)
Guidances (323)
Healthcare (11212)
HIV (29)
Huntington's disease (21)
IgA nephropathy (55)
Immunology and inflammation (125)
Immuno-oncology (8)
Indications (46)
Infectious disease (1645)
Inflammatory bowel disease (131)
Inflation Reduction Act (13)
Influenza (64)
Intellectual property (163)
Interviews (244)
IPO (12163)
IRA (54)
Job creations (2977)
Job search strategy (1122)
Kidney cancer (12)
Labor market (66)
Layoffs (307)
Leadership (26)
Legal (5152)
Liver cancer (61)
Longevity (8)
Lung cancer (403)
Lymphoma (205)
Machine learning (29)
Management (47)
Manufacturing (527)
MASH (107)
Medical device (8196)
Medtech (8214)
Mergers & acquisitions (16025)
Metabolic disorders (711)
Multiple sclerosis (95)
NASH (16)
Neurodegenerative disease (130)
Neuropsychiatric disorders (30)
Neuroscience (1754)
NextGen: Class of 2025 (4289)
Non-profit (1996)
Now hiring (27)
Obesity (338)
Opinion (267)
Ovarian cancer (104)
Pain (135)
Pancreatic cancer (129)
Parkinson's disease (166)
Partnered (21)
Patents (350)
Patient recruitment (236)
Peanut (26)
People (47234)
Pharmaceutical (72)
Pharmacy benefit managers (25)
Phase I (15444)
Phase II (22380)
Phase III (17286)
Pipeline (2270)
Policy (228)
Postmarket research (1707)
Preclinical (6134)
Press Release (59)
Prostate cancer (138)
Psychedelics (29)
Radiopharmaceuticals (216)
Rare diseases (482)
Real estate (4451)
Recruiting (63)
Regulatory (17558)
Reports (43)
Research institute (1364)
Resumes & cover letters (244)
Rett syndrome (15)
RNA editing (9)
RSV (32)
Schizophrenia (106)
Series A (146)
Series B (100)
Service/supplier (6)
Sickle cell disease (60)
Special edition (20)
Spinal muscular atrophy (102)
Sponsored (30)
Startups (2623)
State (2)
Stomach cancer (10)
Supply chain (78)
Tariffs (89)
The Weekly (62)
Vaccines (464)
Venture capital (50)
Weight loss (221)
Women's health (34)
Worklife (16)
Date
Today (110)
Last 7 days (492)
Last 30 days (1987)
Last 365 days (23210)
2025 (18949)
2024 (26340)
2023 (29981)
2022 (39078)
2021 (41191)
2020 (39391)
2019 (32672)
2018 (24566)
2017 (24092)
2016 (22473)
2015 (26412)
2014 (20098)
2013 (16752)
2012 (18249)
2011 (18987)
2010 (17067)
Location
Africa (573)
Alabama (43)
Alaska (5)
Arizona (149)
Arkansas (7)
Asia (33386)
Australia (6295)
California (6555)
Canada (2265)
China (734)
Colorado (291)
Connecticut (327)
Delaware (170)
Europe (66238)
Florida (1051)
Georgia (166)
Hawaii (2)
Idaho (33)
Illinois (562)
India (44)
Indiana (322)
Iowa (12)
Japan (262)
Kansas (98)
Kentucky (30)
Louisiana (14)
Maine (50)
Maryland (844)
Massachusetts (4897)
Michigan (211)
Minnesota (321)
Mississippi (3)
Missouri (83)
Montana (17)
Nebraska (20)
Nevada (92)
New Hampshire (67)
New Jersey (2092)
New Mexico (15)
New York (1947)
North Carolina (1011)
North Dakota (8)
Northern California (3014)
Ohio (210)
Oklahoma (14)
Oregon (26)
Pennsylvania (1438)
Puerto Rico (15)
Rhode Island (31)
South America (899)
South Carolina (44)
Southern California (2593)
Tennessee (117)
Texas (1015)
United States (24611)
Utah (170)
Virginia (196)
Washington D.C. (63)
Washington State (579)
West Virginia (4)
Wisconsin (59)
494,233 Results for "teva pharmaceutical industries limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Obesity
Teva Brings First GLP-1 Generic for Obesity, Targets Novo’s Saxenda
In December 2024, Teva also secured FDA approval for the other liraglutide brand Victoza, indicated for type 2 diabetes.
August 29, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe
October 20, 2025
·
4 min read
Press Releases
Teva Releases Q3 2025 Aide Memoire
September 25, 2025
·
2 min read
Press Releases
Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy
September 10, 2025
·
6 min read
Press Releases
Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025
September 25, 2025
·
2 min read
Press Releases
Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September 2025
September 3, 2025
·
2 min read
Business
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
Teva Pharmaceutical Industries Ltd. today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company’s manufacturing and supply division, effective June 3, 2024.
May 15, 2024
·
7 min read
Policy
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
UroGen Pharma Ltd. today announced that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries, Ltd., alleging infringement of U.S. Patent Numbers 9,040,074 (“the ’074 patent”) and 9,950,069.
April 3, 2024
·
9 min read
Pharm Country
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States
Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of an authorized generic of Victoza®1 (liraglutide injection 1.8mg), in the United States.
June 24, 2024
·
9 min read
Press Releases
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
August 29, 2025
·
10 min read
1 of 49,424
Next
